EFAVIRENZ | A077673 | AUROBINDO PHARMA LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizens Petition from Lachman Consultant Services, Inc. FDA-2005-P-0515 · 7 docket documents Lachman Consultant Services, Inc. submitted this petition under Section 505(j)(2)(C) requesting that the FDA declare Efavirenz Tablets for Oral Suspension in 50 mg, 100 mg, and 200 mg strengths suitable for submission in an ANDA, with the reference-listed drug being Sustiva efavirenz Capsules 200 mg | Other | 2010-01-21 | Withdrawn | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.43
per ea
Lowest NADAC/Unit
$1.43
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65862004930EFAVIRENZ 600 MG TABLET | $1.43 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.